By Dean Seal
Shares of Septerna sank to their lowest level yet after the company said it would end the phase 1 clinical trial for SEP-786 as a treatment for hypoparathyroidism.
The stock fell 68% to a low of $4.17 in early trading. The stock just hit the market last fall.
The clinical-stage biotech company said Tuesday that it would stop the trial based on two unanticipated and severe events that didn't cause liver injury or other serious adverse effects, but prompted the discontinuation of dosing for both study participants.
The company said it would initiate non-clinical studies to investigate what was observed during phase 1.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 18, 2025 10:26 ET (15:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.